医学
体外光采
重症监护医学
鲁索利替尼
疾病
限制
生物制剂
疾病管理
造血干细胞移植
移植
生物仿制药
临床试验
免疫学
评论文章
梅德林
干细胞
移植物抗宿主病
疾病控制
体外
生物信息学
美罗华
危险分层
风险评估
专家意见
造血干细胞
作者
Monica Passannante,Antonella Laudisi,Anna Ghiso,Giulia Francia,Carmen Di Grazia,Alida Dominietto,Stefania Bregante,Riccardo Varaldo,Massimiliano Gambella,Emanuele Angelucci,Anna Maria Raiola
标识
DOI:10.1080/17474086.2026.2760637
摘要
INTRODUCTION: Acute graft-versus-host disease (aGVHD) remains a leading cause of morbidity and non-relapse mortality after allogeneic hematopoietic cell transplantation. Despite progress in prophylactic strategies, its management remains challenging: corticosteroids are still the mainstay of first-line care, yet a substantial proportion of patients fail to achieve durable responses, underscoring the need for more effective and less toxic alternatives. AREAS COVERED: This review outlines the current approach to aGVHD, from first-line management to steroid-refractory disease and beyond. It covers corticosteroid optimization, the established role of ruxolitinib in the steroid-refractory setting, and the use of extracorporeal photopheresis in selected patients. Cellular, microbiome-based, cytokine-directed, and regenerative strategies acting on complementary pathogenic mechanisms are also discussed. The literature was identified through a PubMed search using the terms 'acute graft-versus-host disease' and 'treatment,' including publications up to 30 June 2026, supplemented by manual screening of reference lists. EXPERT OPINION: Ruxolitinib has reshaped the management of steroid-refractory aGVHD, although important unmet needs persist. Future progress will depend not only on new agents but on smarter use of existing options: minimizing steroid exposure, refining sequencing, and integrating combinations earlier. Biomarker-guided risk stratification may ultimately support a more individualized approach, improving disease control while limiting toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI